Englert R G, Barlage U
Clinical Research Pfizer/Mack, Karlsruhe, Gars am Inn, West Germany.
Am Heart J. 1991 Jan;121(1 Pt 2):311-6. doi: 10.1016/0002-8703(91)90864-e.
When doxazosin was given to patients with hypertension not adequately controlled by beta-blockade, blood pressure was normalized in 94% of the 34 patients (blood pressure less than or equal to 140/85 mm Hg). This reduction in blood pressure was obtained with doxazosin in combination with metoprolol or oxprenolol at a mean final daily dose of 1.3 mg or pindolol or atenolol at 2.0 mg/day. Exercise-induced increase in systolic and diastolic blood pressure was also lower with combined beta-blocker and doxazosin therapy than with beta-blocker alone. After 12 weeks of treatment, the combination of doxazosin and beta-blocker significantly reduced total serum cholesterol and triglyceride levels. All side effects were mild and only one patient was withdrawn from therapy.
当将多沙唑嗪给予那些血压未被β受体阻滞剂充分控制的高血压患者时,34例患者中有94%的患者血压恢复正常(血压小于或等于140/85 mmHg)。多沙唑嗪与美托洛尔或氧烯洛尔联合使用,平均最终日剂量为1.3 mg,或与吲哚洛尔或阿替洛尔联合使用,日剂量为2.0 mg,可实现血压降低。联合使用β受体阻滞剂和多沙唑嗪治疗时,运动诱发的收缩压和舒张压升高也低于单独使用β受体阻滞剂。治疗12周后,多沙唑嗪与β受体阻滞剂联合使用可显著降低总血清胆固醇和甘油三酯水平。所有副作用均较轻微,只有1例患者退出治疗。